Cisplatin (CDDP): DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (A8321, APExBIO) is a platinum-based chemotherapeutic compound that forms DNA crosslinks, resulting in cell cycle arrest and apoptosis in cancer cells (Qi et al., 2025). It exerts cytotoxicity primarily by activating the p53 pathway and caspase-3/-9-dependent apoptosis (APExBIO). Cisplatin is a gold-standard agent for benchmarking chemoresistance and apoptosis assays across in vitro and in vivo cancer models. Its solubility and storage conditions are critical for reproducible results. Recent studies highlight its role in overcoming cancer stem cell-mediated drug resistance, especially in models of oral and ovarian cancer (Qi et al., 2025).

Biological Rationale

Cisplatin (CDDP) is a small-molecule platinum complex (Cl₂H₆N₂Pt; MW 300.05 g/mol) used extensively in cancer research for its capacity to induce DNA damage and apoptosis (APExBIO). Cancer cells, such as those in oral squamous cell carcinoma (OSCC), often exhibit defects in DNA repair pathways, making them susceptible to DNA crosslinking agents (Qi et al., 2025). Cisplatin is used to probe mechanisms of chemotherapy resistance, apoptosis induction, and tumor growth suppression. It is particularly valuable for studying cancer stem cells (CSCs), which play a pivotal role in recurrence and multidrug resistance (Qi et al., 2025).

Mechanism of Action of Cisplatin

Cisplatin acts by forming intra- and inter-strand crosslinks at guanine N7 positions within DNA. This crosslinking distorts the DNA helix, impeding both replication and transcription (see also: This article extends previous mechanistic summaries by integrating recent apoptosis pathway data). DNA damage leads to activation of the p53 tumor suppressor, which in turn triggers cell cycle arrest and initiates the intrinsic apoptosis pathway. Caspase-9 is recruited and activated, resulting in downstream activation of caspase-3 and subsequent cellular apoptosis (Qi et al., 2025). In addition, cisplatin increases intracellular reactive oxygen species (ROS), driving oxidative stress and further promoting cell death via ERK-dependent signaling. This multifaceted mechanism underlies its effectiveness in killing rapidly dividing tumor cells.

Evidence & Benchmarks

• Cisplatin forms DNA crosslinks, leading to apoptosis in oral squamous cell carcinoma models (Qi et al., 2025).
• APExBIO’s Cisplatin (A8321) displays high efficacy in apoptosis induction assays with reproducible results across laboratories (APExBIO).
• In vivo, intravenous administration at 5 mg/kg on days 0 and 7 significantly inhibits tumor growth in xenograft models (Qi et al., 2025).
• Cisplatin is insoluble in water and ethanol, but soluble in DMF at ≥12.5 mg/mL; DMSO should be avoided as it inactivates the compound (APExBIO).
• β-catenin silencing sensitizes OSCC to cisplatin, indicating synergy with WNT pathway inhibitors (Qi et al., 2025).
• Targeting CD133⁺ cancer stem cells combined with cisplatin treatment reduces recurrence in OSCC models (Qi et al., 2025).

Applications, Limits & Misconceptions

Cisplatin’s primary applications include:

• Standard agent for apoptosis and cytotoxicity assays in cancer research (This article provides updated benchmarks over prior work by comparing inter-lab reproducibility.).
• Studying chemotherapy resistance and DNA damage repair pathways in various cancer models.
• Evaluating tumor growth inhibition in xenograft systems, especially when combined with CSC-targeting strategies.

Common Pitfalls or Misconceptions

• DMSO as a solvent: DMSO inactivates cisplatin; only use DMF or saline for dissolution (APExBIO).
• Solution stability: Cisplatin solutions are unstable and should be freshly prepared; storage as a powder in the dark at room temperature is recommended.
• Spectrum of activity: Not all tumors respond equally; resistance is common in recurrent or CSC-rich malignancies (Qi et al., 2025).
• ROS generation: While ROS is a key cytotoxic mechanism, excessive ROS scavengers in the medium can blunt cisplatin efficacy.
• Cell type specificity: Non-dividing or quiescent cells are less sensitive to cisplatin-induced DNA damage.

Workflow Integration & Parameters

For experimental workflows, Cisplatin (A8321) from APExBIO is recommended in powder form, stored in the dark at room temperature for maximum stability. Dissolve only in DMF (≥12.5 mg/mL) to avoid inactivation. Warming and ultrasonic treatment enhance dissolution efficiency. Solutions should be freshly prepared prior to use. For in vivo studies, intravenous administration at 5 mg/kg (days 0 and 7) robustly inhibits tumor growth in xenograft models (Qi et al., 2025). For apoptosis assays, dose ranges of 1–20 µM are commonly used, depending on cell type and protocol (This article expands on practical workflow bottlenecks, providing detailed troubleshooting not covered here.).

Conclusion & Outlook

Cisplatin remains a benchmark DNA crosslinking chemotherapeutic for cancer research. Its ability to induce caspase-dependent apoptosis and inhibit tumor growth in diverse models makes it indispensable for studies of chemotherapy resistance, apoptosis mechanisms, and CSC-targeted therapies. As new delivery technologies and combination strategies evolve, this review adds insights on innovative delivery and resistance-overcoming strategies, moving beyond the core biochemical mechanisms detailed here. Investigators should adhere to best-practice handling and storage protocols to maximize reproducibility and efficacy.